US4330550A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oxoimidazolinealkanoic acids and their salts and esters, their preparation and pharmaceutical compositions containing them
Assignee: A NATTERMANN & CIE A CORP OF WEST GERMANY GmbH
•
Filing: 1980-08-15
•
Granted: 1982-05-18
•
Expires: 2000-08-15
Abstract
Abstract ω-(2-Oxo-4-imidazolin-1-yl) alkanoic acids and salts and esters thereof of the formula: ##STR1## in which n denotes an integer from 1 to 8, R 1 denotes H, a non-toxic cation or a straight-chain or branched, saturated hydrocarbon group of 1 to 6 carbon atoms, and R 2 denotes an unsubstituted or substituted aromatic radical of formula ##STR2## or naphthyl, the substituents X and Y being identical or different and each representing H, halogen or alkoxy have strong antithrombotic activity and an analgesic effect.
Inventors
- 👤 Hans-Heiner Lautenschlager
- 👤 Hans Betzing
- 👤 Brigitte Stoll
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 22:43
CPC Classifications
C; C07; C07D; C07D233/00; C07D233/54; C07D233/66; C07D233/70; A; A61; A61P; A61P7/00; A61P7/02; C07D263/00; C07D263/02; C07D263/30; C07D263/34; C07D263/36; C07D263/38
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
80 words
ω-(2-Oxo-4-imidazolin-1-yl)-alkanoic acids, salts and ester thereof of the formula ##STR48## in which n denotes an integer from 1 to 8, R 1 denotes H, a non-toxic cation, or a straight-chain or branched saturated hydrocarbon group of 1 to 6 carbon atoms, and R 2 is selected from the group consisting of naphthyl, or an unsubstituted or substituted aromatic radical of formula ##STR49## wherein the substituents X and Y, which may be the same or different, represent H, halogen or alkoxy.
Claim 2
Dependent Claim
80 words
ω-(2-Oxo-4-imidazolin-1-yl)-alkanoic acids, salts and ester thereof of the formula ##STR48## in which n denotes an integer from 1 to 8, R 1 denotes H, a non-toxic cation, or a straight-chain or branched saturated hydrocarbon group of 1 to 6 carbon atoms, and R 2 is selected from the group consisting of naphthyl, or an unsubstituted or substituted aromatic radical of formula ##STR49## wherein the substituents X and Y, which may be the same or different, represent H, halogen or alkoxy.
Claim 3
Dependent Claim
9 words
8-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-caprylic acid and pharmaceutically tolerated salts and esters thereof.
Claim 4
Dependent Claim
9 words
8-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-caprylic acid and pharmaceutically tolerated salts and esters thereof.
Claim 5
Dependent Claim
9 words
7-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 6
Dependent Claim
9 words
7-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 7
Dependent Claim
9 words
(2-Oxo-5-phenyl-4-imidazolin-1-yl)-acetic acid and pharmaceutically tolerated salts and esters thereof.
Claim 8
Dependent Claim
9 words
(2-Oxo-5-phenyl-4-imidazolin-1-yl)-acetic acid and pharmaceutically tolerated salts and esters thereof.
Claim 9
Dependent Claim
9 words
5-(4-Chlorophenyl)-2-oxo-4-imidazolin-1-yl-acetic acid and pharmaceutically tolerated salts and esters thereof.
Claim 10
Dependent Claim
9 words
5-(4-Chlorophenyl)-2-oxo-4-imidazolin-1-yl-acetic acid and pharmaceutically tolerated salts and esters thereof.
Claim 11
Dependent Claim
9 words
7-[5-(4-Chlorophenyl)-2-oxo-4-imidazolin-1-yl]-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 12
Dependent Claim
9 words
7-[5-(4-Chlorophenyl)-2-oxo-4-imidazolin-1-yl]-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 13
Dependent Claim
9 words
6-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-caproic acid and pharmaceutically tolerated salts and esters thereof.
Claim 14
Dependent Claim
9 words
6-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-caproic acid and pharmaceutically tolerated salts and esters thereof.
Claim 15
Dependent Claim
9 words
9-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-pelargonic acid and pharmaceutically tolerated salts and esters thereof.
Claim 16
Dependent Claim
9 words
9-(2-Oxo-5-phenyl-4-imidazolin-1-yl)-pelargonic acid and pharmaceutically tolerated salts and esters thereof.
Claim 17
Dependent Claim
9 words
7-[5-(4-Methoxyphenyl)-2-oxo-4-imidazolin-1-yl]-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 18
Dependent Claim
9 words
7-[5-(4-Methoxyphenyl)-2-oxo-4-imidazolin-1-yl]-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 19
Dependent Claim
9 words
7-[5-(3-Bromo-4-methoxyphenyl)-2-oxo-4-imidazolin-1-yl]-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 20
Dependent Claim
9 words
7-[5-(3-Bromo-4-methoxyphenyl)-2-oxo-4-imidazolin-1-yl]-heptanoic acid and pharmaceutically tolerated salts and esters thereof.
Claim 21
Dependent Claim
9 words
8-[5-(1-Naphthyl)-2-oxo-4-imidazolin-1-yl]-caprylic acid and pharmaceutically tolerated salts and esters thereof.
Claim 22
Dependent Claim
9 words
8-[5-(1-Naphthyl)-2-oxo-4-imidazolin-1-yl]-caprylic acid and pharmaceutically tolerated salts and esters thereof.
Claim 23
Dependent Claim
141 words
A process for the preparation of an ω-(2-oxo-4-imidazolin-1-yl)-alkanoic acid represented by the structural formula ##STR50## in which n denotes an integer from 1 to 8, and R 2 is selected from the group consisting of naphthyl, or aromatic radical of formula ##STR51## wherein the substituents X and Y, which may be the same or different, represent H, halogen or alkoxy; which comprises reacting a compound of the formula: ##STR52## in which R 2 is as defined above, in an aprotic organic solvent, with an ω-alkoxycarbonylalkyl isocyanate of the formula: O═C═N--(CH.sub.2).sub.n --COOR III wherein n is as defined above and R is methyl or ethyl, to give the intermediate of the formula: ##STR53## in which R, R 2 and n are as defined above; and contacting said intermediate with an acid in a manner sufficient to yield the compound of formula I.
Claim 24
Dependent Claim
141 words
A process for the preparation of an ω-(2-oxo-4-imidazolin-1-yl)-alkanoic acid represented by the structural formula ##STR50## in which n denotes an integer from 1 to 8, and R 2 is selected from the group consisting of naphthyl, or aromatic radical of formula ##STR51## wherein the substituents X and Y, which may be the same or different, represent H, halogen or alkoxy; which comprises reacting a compound of the formula: ##STR52## in which R 2 is as defined above, in an aprotic organic solvent, with an ω-alkoxycarbonylalkyl isocyanate of the formula: O═C═N--(CH.sub.2).sub.n --COOR III wherein n is as defined above and R is methyl or ethyl, to give the intermediate of the formula: ##STR53## in which R, R 2 and n are as defined above; and contacting said intermediate with an acid in a manner sufficient to yield the compound of formula I.
Claim 25
Dependent Claim
29 words
The process according to claim 12, in which the compound of formula IV is converted into the acid of formula I by treatment with glacial acetic acid and HBr.
Claim 26
Dependent Claim
28 words
The process according to claims 12, in which the reaction of the compounds of formulae II and III is carried out in the presence of a basic catalyst.
Claim 27
Dependent Claim
131 words
The process according to claim 12 which comprises dissolving a compound of structural formula II in dimethylformamide; adding a compound of formula III to said solution and stirring the resulting mixture for about 24 hours at a temperature between about 50° and 60° C. to form the intermediate carboxamide compound of formula IV; precipitating said carboxamide with water; recovering and drying said precipitate in vacuo at room temperature; recrystallizing the crude product from ethanol; contacting said product with a mixture of glacial acetic acid and hydrobromic acid and heating the resulting mixture for about 2 hours; evaporating the volatiles of said mixture in vacuo to yield a residue; stirring the residue with water to precipitate a compound as represented by formula I; washing said precipitate with water and recovering the same.
Claim 28
Dependent Claim
29 words
The process of claim 12 which further comprises reacting the free acid of formula I derived from claim 12 with a non-toxic base or carbonate salt in a solvent.
Claim 29
Dependent Claim
16 words
The process according to claim 16 in which the said salt is an alkali metal salt.
Claim 30
Dependent Claim
49 words
The process of claim 12 which further comprises mixing the acid of formula I with alcohol and anhydrous sodium bicarbonate; stirring the resulting mixture at a temperature sufficient to dissolve the bicarbonate and acid; concentrating the solution to dryness in vacuo and recovering the corresponding salt of the acid.
Claim 31
Dependent Claim
56 words
The process of claim 12 which further comprises reacting the free acid of formula I in the presence of an acid catalyst, with an alcohol of the formula R 1 OH in which R 1 is a straight-chain or branched saturated hydrocarbon group of 1 to 6 carbon atoms to yield the ester of said acid.
Claim 32
Dependent Claim
84 words
The process according to claim 19 which comprises mixing the acid of formula I with methanol; passing hydrogen chloride into the mixture; when the hydrogen chloride has reached the saturation point in said mixture heating the mixture under reflux for 2 hours while continuing to pass hydrogen chloride therethrough; concentrating the mixture in vacuo and dissolving the corresponding methyl ester of the acid in chloroform; extracting said ester containing chloroform solution with Na 2 CO 3 ; and washing the extracted product with water.
Claim 33
Dependent Claim
30 words
An antithrombotic pharmaceutical composition comprising an antithrombotically effective amount of a compound as claimed in any one of claims 1 to 11 together with a pharmaceutically suitable diluent or excipient.
Claim 34
Dependent Claim
11 words
A composition according to claim 21, which additionally contains an anticoagulant.
Claim 35
Dependent Claim
19 words
A composition according to claim 22 in which the anticoagulant is heparin, a heparin salt or a coumarin derivative.
Claim 36
Dependent Claim
23 words
A composition according to claim 21, wherein the pharmaceutically suitable diluent or excipient are selected to provide tablets, dragees, ampoules or injectable solutions.
References Cited (Backward Citations)
US4090025A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-05-17 | 1985-11-16 | 1986-05-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-05-17 | 1989-11-16 | 1990-05-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-05-17 | 1993-11-16 | 1994-05-18 | $7700.00 | Window Closed / Lapsed |